Table of Content

1. Introduction to LAG-3 Inhibitor
1.1 Overview Of LAG-3 inhibitors
1.2 Mechanism of Action
1.3 LAG-3 Targeted Therapy Approaches
1.3.1 Targeting LAG-3 With Fusion Proteins
1.3.2 Targeting LAG-3 With Monoclonal Antibodies
1.3.3 Targeting LAG-3 With Bispecific Antibodies


2. LAG-3 Targeted Therapy In By Indication
2.1 Cancer
2.2 Viral Infections
2.3 Autoimmune Diseases
2.4 Parkinson Disease


3. Opdualag – 1st Approved LAG-3 Inhibitor Clinical Insight


4. Opdualag – 1st Approved LAG-3 Inhibitor Commercial Insight
4.1 Overview & Patent Analysis
4.2 Pricing & Dosage Analysis
4.3 Sales Analysis


5. Global LAG-3 Inhibitor Market
5.1 Current Market Overview
5.2 Market Opportunity Assessment


6. Global LAG-3 Inhibitor Clinical Trials Overview
6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Patient Segment
6.5 By Phase


7. Global LAG-3 Inhibitor Clinical Trials Insight 2023 -2028
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Phase-III


8. Global LAG-3 Inhibitor Market Dynamics
8.1 Market Drivers & Opportunities
8.2 Commercialization Challenges


9. Global LAG-3 Inhibitor Market Future Outlook


10. Competitive Landscape
10.1 Abeome Corporation
10.2 ABL Bio
10.3 Agenus
10.4 Akeso Biopharma
10.5 AnaptysBio
10.6 Bristol-Myers Squibb
10.7 Cancer Research UK
10.8 F-Star Therapeutics
10.9 Immutep
10.10 Incyte Corporation
10.11 Innovent Biologics
10.12 Ligand Pharmaceuticals
10.13 Merck
10.14 Shanghai Fosun Pharmaceutical
10.15 Y-Biologics



List of Figures

Figure 1-1: LAG-3/MHC Class II Signaling Pathway
Figure 1-2: LAG-3 Inhibitor – Mechanism of Action
Figure 1-3: Binding Efficacy of Bispecific Antibodies

Figure 2-1: LAG-3 Signaling in Cancer Cell
Figure 2-2: LAG-3 on T Cells During HIV Infection
Figure 2-3: LAG-3 Associated Autoimmune Diseases
Figure 2-4: Implication of LAG-3 in PD Progression
Figure 2-5: Biomarker Potential of LAG-3 in Parkinson Disease

Figure 4-1: Opdualag – Years Of Approval
Figure 4-2: Opdualag – FDA Orphan & Priority Review Designation Year
Figure 4-3: Neo ReNi II Study – Estimated Starting & Ending Years
Figure 4-4: RELATIVITY-127 Study – Estimated Starting & Ending Years
Figure 4-5: US – Price Of 20ml Vial Of Opdualag (US$), February, 2023
Figure 4-6: US/Global – Opdualag Quarterly Sales (US$ Million), 2022

Figure 5-1: Global – Cancer Immunotherapy Market Size (US$ Billion), 2023 - 2028
Figure 5-2: Global – LAG-3 Inhibitor Market Opportunity by 1% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-3: Global – LAG-3 Inhibitor Market Opportunity by 2% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-4: Global – LAG-3 Inhibitor Market Opportunity by 3% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-5: Global – LAG-3 Inhibitor Market Opportunity by 4% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-6: Global – LAG-3 Inhibitor Market Opportunity by 5% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-7: Global – LAG-3 Inhibitor Market Opportunity by 6% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-8: Global – LAG-3 Inhibitor Market Opportunity by 7% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-9: Global – LAG-3 Inhibitor Market Opportunity by 8% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-10: Global – LAG-3 Inhibitor Market Opportunity by 9% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028
Figure 5-11: Global – LAG-3 Inhibitor Market Opportunity by 10% Cancer Immunotherapy Market (US$ Billion), 2023 - 2028

Figure 6-1: Global – LAG 3 Inhibitor Clinical Trials By Company, 2023 till 2028
Figure 6-2: Global – LAG 3 Inhibitor Clinical Trials By Country, 2023 till 2028
Figure 6-3: Global – LAG 3 Inhibitor Clinical Trials By Indication, 2023 till 2028
Figure 6-4: Global – LAG 3 Inhibitors Clinical Trials By Patient Segment, 2023 till 2028
Figure 6-5: Global – Number of LAG 3 Inhibitors In Clinical Trials By Phase, 2023 till 2028
Figure 8-1: LAG-3 Inhibitor Market Drivers & Opportunities
Figure 8-2: LAG-3 Inhibitor Market Challenges & Restraints
 

List of Tables

Table 4-1: Maximum Infusion Volumes and Concentration Ranges By Patient Group
Table 4-2: Recommended Opdualag Dosage Modifications For Adverse Reactions

Table 10-1: Agenus – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-2: AnaptysBio – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-3: Bristol Myers Squibb – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-4: F-Star – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-5: Immutep – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-6: Incyte Corporation – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-7: Innovent Biologics – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-8: Ligand Pharmaceuticals – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-9: Merck KGaA – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 10-10: Shanghai Fosun Pharmaceutical – Financials & CD223 Antigen Inhibitors Drugs Clinical Trials Insight